medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2005, Número 1

<< Anterior Siguiente >>

Rev Invest Clin 2005; 57 (1)


El gen receptor a dopamina D4 y su asociación con los trastornos mentales

Aguirre-Samudio AJ, Nicolini H

Idioma: Español
Referencias bibliográficas: 59
Paginas: 65-75
Archivo PDF: 277.52 Kb.


RESUMEN

El gen receptor a dopamina D4 (DRD4) ha sido analizado por su estructura, su polimorfismo genético, su constitución proteínica, su distribución neuroanatómica y su respuesta farmacológica. La secuencia del gen DRD4 presenta varios polimorfismos, como del tipo número variable de repetidos en tándem (VNTR) en el exón 3, el VNTR de 12 pares de bases del exón 1 y el polimorfismo único de nucleótidos (SNP) de la región del promotor. El gen DRD4 codifica una proteína transmembranal de 7 dominios, que se distribuye en corteza frontal, en estriado, en hipotálamo y en el hipocampo. Esta revisión discute la importancia biológica del gen DRD4 y sus perspectivas ante nuevas áreas de investigación con énfasis en recientes estudios de asociación en diferentes enfermedades mentales y en comportamientos. El DRD4 es uno de los genes candidatos cuya variación polimórfica ha sido relacionada con algunos trastornos psiquiátricos como esquizofrenia, trastorno de déficit de atención e hiperactividad, obsesivo compulsivo con tics y trastorno por consumo de sustancias, así como con la característica de personalidad de búsqueda de la novedad. El gen DRD4 es un marcador genético y un modelo útil para estudios de asociación, epigenéticos y farmacogenómicos que buscan identificar el origen de trastornos psiquiátricos y comportamientos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kebabian J, Calne D. Multiple receptors for dopamine. Nature 1978; 277: 333-40.

  2. Oliva R. Genoma humano. Barcelona: Masson, S.A.; 1996, p. 53-5.

  3. Van Tol HHM, Bunzow JR, Guan H, Sunahara R, Seeman P, Niznik HB, Civelli O. Cloning of a human dopamine D4 receptor gene with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-14.

  4. Gerlenter J, Kenedy J, Van Tol H, Civelli O, Kidd K. The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. Genomics 1992; 13: 208-10.

  5. Lichter JB, Barr CL, Kennedy J, Van Tol H, Kidd K, Livak K. A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Mol Genet 1993; 2: 767-73.

  6. Van Tol HHM, Wu CM, Guan H-CH, Ohara K, Bunzow JR, Civelli O, Kennedy J, Seeman P, Niznik HB, Jovanovic V. Multiple dopamine D4 receptor variants in the human population. Nature 1992; 358: 149-52.

  7. Okuyama Y, Ishiguro H, Toru M, Arinami T. A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem Byophys Res Commun 1999; 258: 292-5.

  8. Okuyama Y, Ishiguro H, Nankai M, Shibuya H, Watanabe A, Arinami T. Identification of a polymorphisms in the promoter region of DRD4 associated with the human novelty seeking personality trait. Mol Psychiatry 2000; 5: 64-9.

  9. Schetz J, Benjamin P, Sibley D. Nonconserved residues in the second transmembrane- spanning domain of the D4 dopamine receptor are molecular determinants of D4 -Selective pharmacology. Mol Pharmacol 2000; 57: 144-52.

  10. Catalano M, Nobile M, Novelli E, Nöthen M, Smeraldi E. Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol Psichiatry 1993; 34: 459-64.

  11. Seeman M, Chang FM, Deinard A, Quiñones A, Kidd K. Evolution of exon 1 of the dopamine D4 receptor (DRD4) gene in primates. J Exp Zool 2000; 288: 32-8.

  12. Nothen MM, Cichon S, Hemmer S, Hebebrand J, Remschmidt H, Lehnkuhl G, Poustka F, Schmidt M, Catalano M. Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygisity. Hum Mol Genet 1994; 3: 2207-12.

  13. Cichon S, Nöthen M, Catalano M, Di Bella D, Maier W, Lichtermann D, Minges J, Albus M, Borrmann M, Franzek E, Stöber G, Weigelt B, Körner J, Rietschel M, Propping P. Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene. Psychiatric Genet 1995; 5: 97-103.

  14. Strader CD, Candelore M, Hill WS, Sigal IS, Dixon RA. Identification of two serine residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem 1989; 263: 13572-8.

  15. Schetz J, Benjamin P, Sibley D. Nonconserved residues in the second transmembrane- spanning domain of the D4 dopamine receptor are molecular determinants of D4 –Selective pharmacology. Mol Pharmacol 2000; 57: 144-52.

  16. Berger MA, Defagot M, Villar MJ, Antonelli M. D4 dopamine and metabotropic glutamate receptors in cerebral cortex and striatum in rat brain. Neurochem Res 2001; 26: 345-52.

  17. Mulcrone J, Kerwin RW. The regional pattern of D4 gene expression in human brain. Neuroscience Letters 1997; 234: 147-50.

  18. Vanderberg DJ, Rodriguez L, Hivert E, Schiller J, Villareal G, Pugh E, Lachman H, Uhl GR. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-o- methyltransferase (COMT) gene. Am J Med Genet 2000; 96: 678-83.

  19. Cruz C, Camarena B, King N, Páez F, Sidenberg D, De La Fuente JR, Nicolini H. Increased prevalence of the seven-repeat variant of the dopamine D4 receptor gene in patients with obsessive-compulsive disorder with tics. Neuroscience Let 1997; 231: 1-4.

  20. Ebstein RP, Novick O, Umansky R, Priel B, Osher Y, Blaine D. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking. Nature Genet 1996; 12: 78-80.

  21. Cloninger CR, Adolfsson R, Svrakic N. Mapping genes for human personality. Nature Genet 1996; 12: 3-4.

  22. Ronai Z, Szekely A, Nemoda Z, Lakatos K, Gervai J, Staub M, Sasvari-Szekely M. Association between novelty seeking and the -521 C/T polymorphisms in the promotor region of the DRD4 gene. Mol Psychiatry 2001; 6: 35-8.

  23. Faraone S, Doyle A, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D4 receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158: 1052-7.

  24. Schmidt L, Fox N, Perez-Edgar K, Hu S, Hamer D. Association of DRD4 with attention problems in normal childhood development. Psichiatric Genet 2001; 11: 25-9.

  25. Hamilton SP, Haghighi F, Heiman GA, Klein DF, Hodge SE, Fyer AJ, Weissman MM, Knowlws JA. Investigation of dopamine receptor (DRD4) and dopamine transporter (DAT) polymorphisms for genetic linkage or association to panic disorder. Am J Med Genet 2000; 96: 324-30.

  26. Nanko S, Hattori M, Ikeda K, Sasaki T, Tazamatsuri H, Kuwata S. Dopamine D4 receptor polymorphism and schizophrenia. Lancet 1993; 341: 689-90.

  27. Rinetti G, Camarena B, Cruz C, Apiquian R, Fresan A, Paez F, Nicolini H. Dopamine D4 receptor (DRD4) gene polymorphism in the first psychotic episode. Arch Med Res 2001; 32: 35-8.

  28. Palacios Cruz L. Usando la teoría del apego para entender la conducta mórbida. Información Clínica 2003; 9: 50-1.

  29. Lakatos K, Nemoda Z, Toth I, Ronai Z, Ney K, Sasvari-Szekely M, Gervai J. Further evidence for the role of the dopamine D4 receptor (DRD4) gene in attachment disorganization: interaction of the exon III 48 bp repeat and the -521 C/T promoter polymorphisms. Mol Psychiatry 2002; 7: 27-31.

  30. Benjamin J, Li L, Patterson C, Greenberg B, Murphy D, Hamer D et al. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking. Nature Genet 1996; 12: 81-4.

  31. Ono Y, Manki H, Yoshimura K. Association between dopamine D4 receptor exon III polymorphism and novelty seeking in Japanese subjects. Am J Med Genet 1997; 74: 501-3.

  32. Malhotra A, Virkkunen M, Rooney W, Eggert M, Linnoila M, Goldman D. The association between the dopamine D4 receptor (D4DR) 16 amino acid repeat and novelty seeking. Mol Psichiatry 1996; 1: 388-91.

  33. Jönsson E, Noten M, Gustavsson J, Neidt H, Brené S, Tylec A, Propping P. Lack evidence for allelic association between personality traits and the dopamine D4 receptor gene polymorphisms. Am J Psychiatry 1997; 154: 697-9.

  34. Sullivan P, Fifield W, Kennedy M, Mulder R, Sellman J, Joyce P. No association between novelty seeking and the type 4 dopamine receptor gene (DRD4) in two New Zealand samples. Am J Psychiatry 1997; 155: 98-101.

  35. Schinka J, Letsch E, Crawford F. DRD4 and novelty seeking: results of meta-analyses. Am J Med Genet 2002; 114: 643-8.

  36. Mitsuyasu H, Hirata N, Shibata H, Takeda Y, Ninomiya H, Kawasaki H, Tashiro N, Fukumaki Y. Association analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene (DRD4) with schizophrenia and personality traits. J Hum Genet 2001; 46: 26-31.

  37. Serretti A, Lilli R, Lorenzi C, Lattuada E, Smeraldi E. DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: A study on 2,011 affected subjects. Am J Med Gen 2001; 105: 283-90.

  38. Cardon L, Palmer L. Population stratification and spurious allelic association. Lancet 2003; 361: 598-604.

  39. Hedrick P. Genetic of Populations. Massachusetts: Jones and Bartlett Publishers; 2000, chap. 6.

  40. Longstaff A. Neuroscience. UK: Springer – Verlag New York Inc.; 2000, p. 250-4.

  41. Purves D, Augustine G, Fitspatrick D, Katz L, Lamantia A, Mcnamara J. Invitación a la neurociencia. Buenos Aires Argentina: Editorial Médica Panamericana; 2001, p. 152-7.

  42. Bouvier C, Bunzow J, Guan HC, Unteutscha, Civelli O, Grandy D, Van Tol HH. Functional characterization of the human dopamine D4.2 receptor using vaccinia virus as an expression system. Eur J Pharmacol 1995; 290: 11-17.

  43. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol H. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995; 65: 1157-65.

  44. Tarazi F, Baldesarini R. Brain dopamine D4 receptors: basic and clinical status. Int J Neuropsychopharmacol 1999; 2: 41-58.

  45. Kikergaard A, Hammershoj E, Ostergard P. Evaluation of side effects due to clozapine in long-term treatment of psychosis. Arzneim-Forsch/drug Res 1982; 32: 465-8.

  46. Gutiérrez SF. Tratamiento actual con antipsicóticos de la esquizofrenia. Farm Hosp 1998; 22: 207-12.

  47. Petronis A. The genes for major psychosis: aberrant sequence or regulation? Neuropsychopharmacol 2000; 23: 1-12.

  48. Devlin B, Roeder K. Genomic control for association studies. Biometrics 1999; 55: 997-1004.

  49. Bacanu S, Devlin B, Roeder K. The power of genomic control. Am J Human Genet 2000; 66: 1933-44.

  50. Liebermann JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharm 1997; 17: 205-29.

  51. Fatemi SH, Emamian ES, Sidwell RW, Kist DA, Stary JM, Earle JA, Thuras P. Human influenza viral infection in uteri alters glial fibrillary acidic protein immunoreactivity in the developing brains of neonatal mice. Mol Psychiatry 2002; 7: 633-40.

  52. Chen CH, Chiu YL, Shaw CK, Tsai MT, Hwang AL, Hsiao KJ. Detection of Borna disease virus RNA from peripheral blood cells in schizophrenic patients and mental health workers. Mol Psychiatry 1999; 4: 566-640.

  53. Karlsson H, Bachmann S, Schroder J, McArthur J, Fuller Torrey E, Yolken R. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. PNAS 2001; 98: 4634-9.

  54. Aitta-aho T. Neonatal viral brain infection and the development of prepulse inhibition: A neurodevelopmental model schizophrenia. Pro gradu. Sweden: Department of Pharmacy, University of Helsinki; 2003.

  55. Petronis A, Gottesman I, Kan P, Kennedy J, Basile V, Paterson A, Popendikyte V. Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophrenia Bull 2003; 29: 169-78.

  56. Watson R, Curtin G, Doolitle D, Goodman J. Progressive alterations in global and GC- rich DNA methylation during tumorogenesis. Toxicol Sci 2003; 75: 289-99.

  57. El-Osta A. DNMT cooperativity the developing links between methylation, chromatin structure and cancer. Bioessays 2003; 25: 1071-84.

  58. Basile V, Masellis M, Potkin S, Kennedy J. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-30.

  59. Pickar D, Rubinow K. Pharmacogenomics of psychiatric disorders. TIPS 2001; 22: 75-83.




2020     |     www.medigraphic.com